Mabion Capacity Update May 2024: Large Molecule Development
Source: Mabion
Mabion, a biologics CDMO with end-to-end services focusing on recombinant proteins development and production showcases their new installations in upstream development, new bioreactors, as well as downstream development and fill & finish during this presentation from the May 2024 OPCU event. This state-of-the-art EU-GMP certified facility is staffed by a team of 250 professionals and, as of 2023, is focused solely on providing CDMO services to its clients. Capacity is now available and our team is excited to engage in new projects.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
Mabion
This website uses cookies to ensure you get the best experience on our website. Learn more